A Phase 2 interventional study of Intravenous Topotecan and Intravenous Docetaxel in Mediastinal Neoplasms, sponsored by Aultman Health Foundation. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-20.
Sponsored by Aultman Health Foundation · Phase 2, Interventional, and Treatment
The purposes of this study are:
The main objective of this study was to determine the overall response rate of patients treated with at least 2 cycles of topotecan and docetaxel. The secondary objectives were to determine the feasibility and toxicities of this combination. The final secondary objective is overall survival for patients that received 2 or more cycles.
Methods: Eligible pts with recurrent small cell lung cancer had to be at least 3 months from initial treatment. Pts received Docetaxel 30 mg/m2 IV followed by Topotecan 3 mg/m2 IV Days 1 and 8 of a 21 day cycle. Disease assessment was done every 2 cycles. Toxicity was measured each cycle.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 7 is below the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Aultman Health Foundation is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Weekly intravenous topotecan with intravenous docetaxel
Drug: Intravenous Topotecan · Drug: Intravenous Docetaxel
Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
Also known as: Hycamtin
Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 \& 8 of a 21 day cycle
Also known as: Taxotere
To determine the overall response rate of patients treated with at least two cycles of topotecan and docetaxel
To determine the overall response rate of patients treated with at least two cycles of topotecan and docetaxel
Time frame: 3 years
This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aultman Health Foundation